The research mission of our team is to discover and then rapidly introduce into clinical use novel approaches to curing childhood cancer and blood disorders. Our multi-disciplinary approach to research allows our physician-scientists to apply cutting-edge advances in immunology, cancer biology, genetics, and pharmacology to most effectively treat our patients. For example:
- David Loeb, MD, PhD, directs a translational research laboratory focused on understanding bone tumors, metastatic spread, and new approaches to management.
- Deepa Manwani, MD, internationally recognized for her expertise in pediatric hematologic disorders, runs an NIH-funded study of new treatment for sickle cell disease.
- Allison Martin, MD, is an NIH-funded investigator who studies novel immunotherapeutic approaches for children with brain tumors.
- Daniel Weiser, MD, runs a translational research laboratory performing state-of-the-art biomarker testing in osteosarcoma and neuroblastoma.
In addition to offering clinical studies based on discoveries in the research laboratories at CHAM and Albert Einstein College of Medicine, our physicians are committed to providing patients and families with the most current and innovative clinical trials through internationally-recognized consortia including the Children’s Oncology Group (COG), Dana-Farber Cancer Institute (DFCI), and National Pediatric Cancer Foundation.
FIND A CLINICAL TRIAL